Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

MediPharm Labs Corp. (MEDIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1723+0.0123 (+7.69%)
At close: 03:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1600
Open0.1501
BidN/A x N/A
AskN/A x N/A
Day's Range0.1501 - 0.1723
52 Week Range0.1220 - 0.7850
Volume59,909
Avg. Volume229,638
Market Cap45.546M
Beta (5Y Monthly)0.81
PE Ratio (TTM)N/A
EPS (TTM)-0.2360
Earnings DateNov 11, 2021 - Nov 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    MediPharm Labs Completes Payment of All Convertible Debt

    TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has completed all payments required under its 2020 $41 million unsecured convertible debt. “MediPharm continues on its plan and path to profitability, and paying off our convertible debt in full is a major milestone on that path,” said Bryan Howcroft, CEO, Med

  • GlobeNewswire

    MediPharm Labs Receives Award for CBD Brand of the Year

    Kind Awards 2021 CBD Brand of the Year Kind Awards 2021 CBD Brand of the Year MediPharm Labs pharma-quality CBD dominant oil line has been awarded CBD Brand of the year by KIND Magazine.MediPharm Labs’ CBD products have seen steady revenue growth and notoriety in 2021, including on national television on an episode of CBC Marketplace. BARRIE, Ontario, Dec. 22, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical

  • GlobeNewswire

    MediPharm Labs Provides Operational Update and Confirms Profitability Improvement Initiatives are Underway

    Strong cash balance and continued reduction of convertible debt to less than $500K.Opportunities for optimization of the operating strategy between Australia and Canada as the Canadian Drug Establishment Licence (DEL) unlocks many manufacturing and supply chain pathways. These pathways will reduce infrastructure cost, improve delivery times, and increase customer satisfaction.Delivery to five international medical cannabis markets including first deliveries of advanced GMP CBD isolate to traditi

Advertisement
Advertisement